Efficacy and Safety of Insulin Aspart 30 and Insulin Degludec/Aspart vs. Basal Insulin in Patients with Type 2 Diabetes: A Meta-analysis

被引：0
|
作者：
Mishriky, Basem M.
Tanenberg, Robert J.
Cummings, Doyle M.
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
973-P
引用
收藏
页码：A252 / A252
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
    Luo, Qiong
    Zhou, Li
    Zhou, Naitong
    Hu, Ming
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [22] Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes
    Dardano, Angela
    Bianchi, Cristina
    Del Prato, Stefano
    Miccoli, Roberto
    VASCULAR HEALTH AND RISK MANAGEMENT, 2014, 10 : 465 - 475
  • [23] Insulin degludec and insulin degludec/insulin aspart: A guide to their use in diabetes mellitus
    Keating G.M.
    Drugs & Therapy Perspectives, 2013, 29 (10) : 297 - 302
  • [24] Efficacy and safety of fast-acting insulin aspart versus insulin aspart both in combination with insulin degludec with or without metformin in adults with diabetes
    Du, J.
    Wang, G. X.
    Wang, G.
    Liu, M.
    Thamattoor, U. K.
    Luan, Z. J.
    Alibegovic, A. C.
    Mu, Y. M.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S377 - S377
  • [25] A SHORT-TERM COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE U100 AND INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON BASAL INSULIN
    Zhou, L.
    Zhou, N.
    Hu, M.
    VALUE IN HEALTH, 2022, 25 (07) : S386 - S386
  • [26] Efficacy of switching from basal-bolus insulin therapy to twice-daily insulin degludec/insulin aspart co-formulation plus insulin aspart in patients with poorly controlled type 2 diabetes
    Gunes, E.
    Gunes, M.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (14) : 6691 - 6699
  • [27] Safety and efficacy of insulin aspart and soluble human insulin in Type 2 diabetes mellitus
    Cucinotta, D.
    Caputo, S.
    Mannucci, E.
    Nicolucci, A.
    Pellegrini, F.
    Perriello, G.
    Sbraccia, P.
    MINERVA ENDOCRINOLOGICA, 2012, 37 (04) : 357 - 366
  • [28] COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Liu, C.
    Tao, L. B.
    Wang, F.
    VALUE IN HEALTH, 2020, 23 : S111 - S111
  • [29] Insulin Degludec/Insulin Aspart (IDegAsp) Provides Superior FPG Control and Reduced Hypoglycaemia vs. Biphasic Insulin Aspart 30 (BIAsp 30) in Insulin-Naive Adults with Type 2 Diabetes in a Randomized Phase 3 Trial
    Franek, Edward
    Haluzik, Martin
    Canecki-Varzic, Silvija
    Sargin, Mehmet
    Macura, Stanislava
    Zacho, Jeppe
    Christiansen, Jens Sandahl
    DIABETES, 2014, 63 : A225 - A225
  • [30] Insulin Degludec and Insulin Degludec/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus
    Gillian M. Keating
    Drugs, 2013, 73 : 575 - 593
12345